Type Whole antibody Target IL4 receptor alpha CAS Number 1190264-60-8 | ATC code none ChemSpider none | |
 | ||
Tsw 1 year successful new dupilumab treatment
Dupilumab is a monoclonal antibody designed for the treatment of atopic diseases. This drug was developed by Regeneron Pharmaceuticals. The US Food and Drug Administration has designated dupilumab a “breakthrough therapy” which is designed to speed promising new drugs to market.
Contents
Dupilumab potentially revolutionize the treatment of atopic dermatitis
Mechanism of action
It binds to the alpha subunit of the interleukin-4 receptor (IL-4Rα). Through blockade of IL-4Rα, dupilumab modulates signaling of both the interleukin 4 and interleukin 13 pathway.
Medical uses
The interleukin 4 and 13 pathways have been implicated in the pathophysiology of allergic disease, particularly asthma and atopic dermatitis.
Clinical trials
In 2013 mid-stage data was presented at the American Thoracic Society meeting and published in the NEJM demonstrating an 87% (placebo: 67%) reduction in asthma exacerbations in patients with moderate-to-severe allergic asthma. In an atopic dermatitis study, 85%(36 percent or 85 out of 671 patients) of patients improved their symptoms by at least 50% within twelve weeks (measured by eczema area and severity index), versus 35% in the placebo group.
In 2016 good results were announced from the SOLO1 and SOLO2 phase III trials (for atopic dermatitis/eczema symptoms) and the US FDA granted it priority review status with a final decision due by March 2017.